The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries, and is a critically important endeavour for the bleeding disorders community. This month, the World Federation of Hemophilia (WFH) and WFH USA are proud to celebrate the one year anniversary of Bayer joining the WFH Humanitarian Aid Program.
The commitment of Bayer consists of a five-year partnership that will contribute additional Factor VIII treatments to people living with hemophilia A in over 60 countries where the WFH Humanitarian Aid Program is working to help people with little to no access to care. In 2019, Bayer donated 50 million IUs of treatment through the WFH Humanitarian Aid Program—and the company will be building on this accomplishment in the coming years.
“The WFH Humanitarian Aid Program helps fulfill an urgent and important public health challenge and its efforts would not be possible without the support of companies such as Bayer,” said Alain Weill, President, World Federation of Hemophilia.
To read the press release announcing the start of Bayer’s support in 2019, please click here.
About the World Federation of Hemophilia
For over 50 years, the World Federation of Hemophilia (WFH)—an international not-for-profit organization— has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 140 countries and has official recognition from the World Health Organization. To find out more about the WFH, visit www.wfh.org
Charitable solicitations for the common purposes of WFH and WFH USA within the U.S. are conducted through WFH USA, a 501(c)3 affiliated entity.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care.
WFH and WFH USA collaborate to manage and control the WFH Humanitarian Aid Program. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor; Grifols and Roche, our Leadership Contributors; and our Contributor, CSL Behring. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org